Michael Feld, who serves as Executive Vice President and Chief Revenue Officer at Becton Dickinson & Co (NYSE: BDX), sold 75 shares of common stock on March 26, 2026. The shares traded at $156.83 apiece, generating proceeds of $11,762. The disposition was made under a Rule 10b5-1 trading plan that Feld had adopted on February 7, 2025. After completing the sale, Feld retained direct ownership of 21,233 shares of Becton Dickinson common stock.
The insider sale is one element of a series of corporate developments announced by Becton Dickinson in recent disclosures. The company reported fiscal first-quarter 2026 results that exceeded consensus expectations, recording ex-foreign-exchange revenue growth of 0.4% year-over-year. That performance outpaced the company’s guidance, which had forecast low-single-digit declines in revenue for the period.
In parallel with its operating update, Becton Dickinson has initiated tender offers to repurchase up to $1.6 billion of its outstanding debt securities. The program covers 15 different series of debt with varying maturities. The tender offers represent an active effort to address the company’s debt profile.
On the regulatory and product front, Becton Dickinson received FDA clearance for its Surgiphor 1000mL antimicrobial irrigation system. The device is designed to assist during surgical procedures by irrigating wounds and removing debris and microorganisms.
Analyst activity has reflected a mixed view of the company’s near-term prospects. RBC Capital reduced its price target for Becton Dickinson to $172 from $210 while maintaining a Sector Perform rating. Argus also trimmed its target, lowering it to $180 from $230, but kept a Buy rating in place, citing market turbulence as a factor in the adjustment. Raymond James additionally noted that medical technology pricing remained largely flat in 2025 after a brief period of positive movement in prior years. The commentary points to the company’s strategic emphasis on growth opportunities within its Medical and Interventional segments.
Summary of the transaction and company actions
- Michael Feld sold 75 shares on March 26, 2026 at $156.83, totaling $11,762.
- Feld continues to hold 21,233 shares following the sale; the transaction was executed under a Rule 10b5-1 plan adopted February 7, 2025.
- Becton Dickinson reported fiscal Q1 2026 ex-FX revenue growth of 0.4% year-over-year, beating consensus and company guidance.
- The company launched tender offers to buy up to $1.6 billion of outstanding debt across 15 series and received FDA clearance for the Surgiphor 1000mL antimicrobial irrigation system.
- Analysts at RBC Capital and Argus lowered price targets, while commentary from Raymond James highlighted generally flat Med Tech pricing in 2025.
Context notes
The information above reflects company filings, reported results and analyst actions as disclosed. Where specific details were not provided in those disclosures, this account does not expand beyond the available facts.